Clinical Trials Logo

Cannabis Use Disorder, Moderate clinical trials

View clinical trials related to Cannabis Use Disorder, Moderate.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06225232 Not yet recruiting - Clinical trials for Cannabis Use Disorder, Moderate

Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study

PSI_CUD
Start date: March 2024
Phase: Phase 2
Study type: Interventional

Cannabis is the most commonly used psychoactive substance in Canada (Lowry & Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis use that causes performance difficulty at work, school and relationships (Hasin et al., 2013). A review of current treatments available for CUD indicate the lack of a pharmacological and psychological treatment with high success rates, which highlights the importance of exploring potential psychosocial interventions for the treatment of CUD. Given the evidence of psilocybin's therapeutic potential in the treatment of substance use disorders (de Veen et al., 2017), we aim to conduct a study using psilocybin-assisted-psychotherapy in the treatment of CUD. The study aims to evaluate the feasibility, safety, tolerability and potential therapeutic effect of 2 doses [25 mg] of psilocybin administered as part of a 9-week Motivational Enhancement Therapy (MET) and supportive therapy. This trial will be the first to evaluate the potential treatment effects of psilocybin on symptoms of CUD.

NCT ID: NCT04106336 Not yet recruiting - Clinical trials for Cannabis Use Disorder, Moderate

Cortical Excitability and Role of rTMS in Cannabis Use Disorder

Start date: October 1, 2019
Phase: Early Phase 1
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) and cortical excitability have a role in cannabis use disorder